Page last updated: 2024-08-23

epirubicin and Neoplasms, Bone Marrow

epirubicin has been researched along with Neoplasms, Bone Marrow in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (50.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Baak, JP; Gilje, B; Janssen, EA; Nordgård, O; Smaaland, R; Søiland, H; Tjensvoll, K	1
Ariad, S; Bobilev, D; Geffen, DB; Tokar, M	1
Abdallah, A; Bastert, G; Egerer, G; Fersis, N; Funk, L; Goldschmidt, H; Haas, R; Hahn, U; Hohaus, S; Kaul, S; Martin, S; Schlenk, RF; Schneeweiss, A; Wallwiener, D	1
Ardizzoia, A; Barni, S; Giani, L; Lissoni, P; Malugani, F; Mandalà, M; Paolorossi, F; Tancini, G	1

Trials

2 trial(s) available for epirubicin and Neoplasms, Bone Marrow

Article	Year
Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients. Breast cancer research and treatment, 2011, Volume: 128, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cisplatin; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Methotrexate; Middle Aged; Mitotic Index; Neoplasm Micrometastasis; Prognosis; Tamoxifen; Treatment Outcome	2011
Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. Journal of pineal research, 1999, Volume: 26, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Melatonin; Middle Aged; Platelet Count; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome	1999

Article

Year

Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.

Breast cancer research and treatment, 2011, Volume: 128, Issue:1

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cisplatin; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Methotrexate; Middle Aged; Mitotic Index; Neoplasm Micrometastasis; Prognosis; Tamoxifen; Treatment Outcome

2011

Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study.

Journal of pineal research, 1999, Volume: 26, Issue:3

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Melatonin; Middle Aged; Platelet Count; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome

1999

Other Studies

2 other study(ies) available for epirubicin and Neoplasms, Bone Marrow

Article	Year
Disseminated intravascular coagulation at presentation of advanced gastric cancer. The Israel Medical Association journal : IMAJ, 2006, Volume: 8, Issue:12 Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Bone Marrow Neoplasms; Cisplatin; Disease Progression; Disseminated Intravascular Coagulation; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome	2006
Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer. British journal of cancer, 1999, Volume: 79, Issue:9-10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Staging; Prognosis; Receptors, Estrogen; Recombinant Proteins; Tamoxifen; Treatment Outcome	1999

Article

Year

Disseminated intravascular coagulation at presentation of advanced gastric cancer.

The Israel Medical Association journal : IMAJ, 2006, Volume: 8, Issue:12

Topics: Acute Disease; Adult; Antimetabolites, Antineoplastic; Bone Marrow Neoplasms; Cisplatin; Disease Progression; Disseminated Intravascular Coagulation; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome

2006

Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.

British journal of cancer, 1999, Volume: 79, Issue:9-10

Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Staging; Prognosis; Receptors, Estrogen; Recombinant Proteins; Tamoxifen; Treatment Outcome

1999